Difference between revisions of "Dummer R, et al. J. Am. Acad. Dermatol (2016) cited as Ref 600 in DOI: 10.1038/s41392-020-0110-5 (Q9863)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: DOI Identifier (P138): 10.1016/j.jaad.2016.02.1226, #quickstatements; #temporary_batch_1590000649558)
(‎Created claim: Page(s) (P105): 113-125, #quickstatements; #temporary_batch_1590074839150)
 
(5 intermediate revisions by the same user not shown)
Property / PubMed ID
 +
Property / PubMed ID: 27067394 / rank
 +
Normal rank
Property / Publication Date
 +
2016
Timestamp+2016-01-01T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 year
Before0
After0
Property / Publication Date: 2016 / rank
 +
Normal rank
Property / Published In Name String
 +
J. Am. Acad. Dermatol
Property / Published In Name String: J. Am. Acad. Dermatol / rank
 +
Normal rank
Property / Volume
 +
75
Property / Volume: 75 / rank
 +
Normal rank
Property / title
 +
The 12-month analysis from basal cell carcinoma outcomes with LDE225 treatment (BOLT): a phase II randomized double-blind study of sonidegib in patients with advanced basal cell carcinoma (English)
Property / title: The 12-month analysis from basal cell carcinoma outcomes with LDE225 treatment (BOLT): a phase II randomized double-blind study of sonidegib in patients with advanced basal cell carcinoma (English) / rank
 +
Normal rank
Property / Page(s)
 +
113-125
Property / Page(s): 113-125 / rank
 +
Normal rank

Latest revision as of 15:46, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Dummer R, et al. J. Am. Acad. Dermatol (2016) cited as Ref 600 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Dummer R
    0 references
    0 references
    2016
    0 references
    J. Am. Acad. Dermatol
    0 references
    75
    0 references
    The 12-month analysis from basal cell carcinoma outcomes with LDE225 treatment (BOLT): a phase II randomized double-blind study of sonidegib in patients with advanced basal cell carcinoma (English)
    0 references
    113-125
    0 references